Advanced searches left 3/3

Metastatic Colorectal Cancer - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 27 June 2022

* If you want to update the article please login/register

A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer

To determine the realistic response rate of savolitinib in patients with MET-amplified metastatic colorectal cancer, we need to determine the actual response rate of the drug in patients with MET-amplified metastatic colorectal cancer. To discuss the clinical function of savolitinib in patients with MET-amplified metastatic CRC, we'll go into detail. MET amplified metastatic CRC To describe the toxicities of savolitinib in patients with MET amplified metastatic CRC, we'll explore the toxicities of the drug savolitinib. To investigate the effects of RAS mutation status on reactions to savolitinib. OUTLINE: On days 1-28, patients are given savolitinib orally every day.

Source link: https://clinicaltrials.gov/ct2/show/NCT03592641


Phase II Trial of VB-111 in Combination With Nivolumab in Patients With Metastatic Colorectal Cancer (mCRC).

CRC patients with refractory, metastatic CRCs can be tested, To determine the best overall response, please refer to the following criteria: Objectives: To determine the safety and tolerability of VB-111 in combination with nivolumab in patients with refractory, metastatic CRC; Objectives: To determine the best Overall Response Criteria of combined therapy of VB-111 and nivolumab in patients with refractory, metastatic CRC Eligibility: Histopathological confirmation of colorectal cancer metastatic to the liver Patients must have progressed on > two lines of care chemotherapy for colorectal cancer, be intolerant of chemotherapy, or refused prior chemotherapy. The experimental setup: The VB-111 and immune checkpoint inhibition in patients with metastatic CRC Treatment will be administered in cycles consisting of VB-111 every 6 weeks, as well as nivolumab every 2-week until progression or unacceptable toxicity in patients with metastatic CRC treatment will be delivered in cycles involving VB-111 and immune checkpoint inhibition in patients with metastatic CRC treatment.

Source link: https://clinicaltrials.gov/ct2/show/NCT04166383


Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers

In patients with refractory KRAS- or NRAS-mutant metastatic colorectal cancer, the primary aim is to compare the progression-free survival between those randomized to palbociclib/binimetinib and those randomized to trifluridine and tipiracil hydrochloride in patients with refractory metastatic colorectal cancer in patients with refractory KRAS- or NRAS-mutant metastatic colorectal cancer in patients with mutant metastatic mutant metastatic randomized to palbociclib/binimetinimetinib and those placebo ochloride pharmactal disease t mutant metastatic ectal cancer graftis mutant metastatic mutant metastatic ectal cancer ectal disease mutant metastatic mutant metastatic colorectal mutant metastatic mutant Patients with refractory KRAS- or NRAS-mutant metastatic CRC are correlated to a total response rate by Response Evaluation Criteria in Solid Tumors 1. 1 criteria among those randomized to palbociclib/binimetinib or those randomized to TAS-102 in patients with refractory KRAS- or NRAS-mutant metastatic CRC. Patients with refractory KRAS- or NRAS-mutant metastatic CRC were compared to both those randomly assigned to palbociclib/binimetinib and those randomized to TAS-102 in patients with refractory KRAS- or NRAS-mutant metastatic CRC. To determine the effectiveness and tolerability of the suggested phase II dose of palbociclib in combination with binimetinib in patients with refractory KRAS- or NRAS-mutant metastatic CRC, see this paper. With palbociclib/binimetinib or TAS-102, it will be determined if there is a correlation between circulating tumor deoxyribonucleic acid and tumor response or resistance to therapy. Patients with disease progression may also switch to Arm A.

Source link: https://clinicaltrials.gov/ct2/show/NCT03981614


A Phase 2 Study of Dabrafenib and Trametinib in Combination With PDR001 in Patients With BRAFV600E Metastatic Colorectal Cancer

The safety and efficiency of an investigational drug combination are tested in Phase II clinical trials to see if the drug combination works for treating a specific disease. MEK enzymes play a vital role in the MAPK pathway's functioning. Trametinib inhibits the MEK enzymes in order to shut down the MAPK pathway, thus stopping the pathway that helps the cancer cells grow uncontrollably. PDR001 is a drug that binds to PD1 on immune cells and is believed to prevent the binding of PD-L1 and PD-L2. Researchers are hoping that the administration of all three of these medications will aid anti-cancer efforts in reducing or stopping the cancer formation, as well as the ability of your own immune system to damage or destroy the existing cancer cells.

Source link: https://clinicaltrials.gov/ct2/show/NCT03668431


A Phase IB Study of Pembrolizumab in Combination With Pemetrexed and Oxaliplatin in Patients With Chemo-Refractory Metastatic Colorectal Cancer

Patients with chemo-refractory MSS mCRC patients treated with pembrolizumab, and pembrolizumab in combination with pembrolizumab and pembrolizumab were among the study's secondary objectives. xaliplatin is a drug used in tandem with pembrolizumab and pembrolizumab in combination with pembrolizumab and pembrolizumab in patients with pembrolizumab On Day 1 of each 21-day cycle, the first 3 to 6 patients in cohort 2 will be treated at dose level 1 and receive pesalogium 600 mg/m2 IV. If 0 of the 3 initial patients or 1 of 6 patients in the cohort experiences a DLT, the dose for the next cohort will be increased to dose level 2 and pemalatin 120 mg/m2 IV, unless the combination is otherwise ineffective. During the first 21 days Cycle 1 of each dose class in Cohort 2 and beyond, dose limiting toxicity, DLT will be monitored, as well as determination of RP2D. The highest dose level tolerateable without dose limiting toxicities in 2 of 6 patients will be considered the recommended phase 2 dose RP2D and be increased to 12 patients. Cohort 1 and Cohort 2 will be assessed separately.

Source link: https://clinicaltrials.gov/ct2/show/NCT03626922


Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Comparing the progression-free survival of patients receiving high-dose cholecalciferol in combination with standard chemotherapy and bevacizumab with standard chemotherapy and bevacizumab versus those receiving standard-dose vitamin D3 in combination with standard chemotherapy and bevacizumab. To determine the perceived response rate of patients receiving high-dose vitamin D3 in combination with standard chemotherapy + bevacizumab versus those receiving standard chemotherapy + bevacizumab in combination with standard chemotherapy + bevacizumab. To determine the overall survival of patients receiving high-dose vitamin D3 in combination with standard chemotherapy + bevacizumab versus those receiving standard chemotherapy + bevacizumab in combination with standard chemotherapy + bevacizumab. To estimate and compare the risks of supplementing high-dose vitamin D3 versus standard-dose vitamin D3 to chemotherapy + bevacizumab, please visit and compare the effects. In subgroups of patients defined by baseline plasma calcifediol levels, it was determined by standard-dose vitamin D3's effectiveness against standard-dose vitamin D3's effectiveness. Patients in Arm I receive bevacizumab and chemotherapy as a result of Arm II.

Source link: https://clinicaltrials.gov/ct2/show/NCT04094688


Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab

FOLFIRI plus bevacizumab patients in 100 metastatic colorectal cancer patients will benefit from a genotype-guided dosing scheme for irinotecan to prospectively assess efficacy in 100 metastatic colorectal cancer patients receiving FOLFIRI plus bevacizumab. In *28 homozygotes, there is a small elevated risk of neutropenia in comparison to the conventional irinotecan dose used in FOLFIRI. Patients with these low risk genotypes have a low risk of adverse outcomes, according to the studies, patients with these low risk genotypes may be able to tolerate higher doses of irinotecan in FOLFIRI. The results were published in a phase I study in which *1/*28 and *1/*1 genotypes were able to tolerate increasing doses of irinotecan up to 260 mg/m2 and 310 mg/m2, respectively. In this case, the primary hypothesis is that increasing the irinotecan dose in *1/*28 and *1/*1 genotypes will raise the overall benefit of FOLFIRI for patients with mCRC, as these two groups are likely under-dosed with the new dosing regimen.

Source link: https://clinicaltrials.gov/ct2/show/NCT02138617


Bevacizumab Plus mFOLFOXIRI or mFOLFOX-6 as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer: a Randomised, Open-label, Phase 3 Trial

Both European and American populations were among the latest scientific trials and results on the triplet regimen, as well as bevacizumab for first-line treatment of metastatic colorectal cancer. As a first-line multicenter, randomized, controlled phase III clinical trial in patients with advanced colorectal cancer, this research aims to demonstrate an improved triplet regimen containing bevacizumab and bevacizumab as a first-line multicenter, randomized, controlled trial.

Source link: https://clinicaltrials.gov/ct2/show/NCT04230187

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions